DE69900249T2 - Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie - Google Patents

Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie

Info

Publication number
DE69900249T2
DE69900249T2 DE69900249T DE69900249T DE69900249T2 DE 69900249 T2 DE69900249 T2 DE 69900249T2 DE 69900249 T DE69900249 T DE 69900249T DE 69900249 T DE69900249 T DE 69900249T DE 69900249 T2 DE69900249 T2 DE 69900249T2
Authority
DE
Germany
Prior art keywords
fibrate
metformin
pharmaceutical composition
treating hyperglycaemia
hyperglycaemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69900249T
Other languages
English (en)
Other versions
DE69900249D1 (de
Inventor
Yves Bonhomme
Philippe Briet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of DE69900249D1 publication Critical patent/DE69900249D1/de
Publication of DE69900249T2 publication Critical patent/DE69900249T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
DE69900249T 1998-02-12 1999-01-30 Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie Expired - Lifetime DE69900249T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9801709A FR2774591B1 (fr) 1998-02-12 1998-02-12 Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
PCT/EP1999/000614 WO1999040904A2 (en) 1998-02-12 1999-01-30 Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia

Publications (2)

Publication Number Publication Date
DE69900249D1 DE69900249D1 (de) 2001-10-04
DE69900249T2 true DE69900249T2 (de) 2002-06-13

Family

ID=9522912

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69900249T Expired - Lifetime DE69900249T2 (de) 1998-02-12 1999-01-30 Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie

Country Status (28)

Country Link
US (1) US6372790B1 (de)
EP (1) EP1054665B1 (de)
JP (1) JP4767411B2 (de)
KR (1) KR100567608B1 (de)
CN (1) CN1151785C (de)
AR (1) AR018286A1 (de)
AT (1) ATE204754T1 (de)
AU (1) AU746821B2 (de)
BR (1) BRPI9907866B8 (de)
CA (1) CA2320039C (de)
CZ (1) CZ290101B6 (de)
DE (1) DE69900249T2 (de)
DK (1) DK1054665T3 (de)
ES (1) ES2162517T3 (de)
FR (1) FR2774591B1 (de)
HK (1) HK1034913A1 (de)
HU (1) HU224619B1 (de)
ID (1) ID26254A (de)
MY (1) MY118164A (de)
NO (1) NO328314B1 (de)
PL (1) PL196874B1 (de)
PT (1) PT1054665E (de)
RU (1) RU2207850C2 (de)
SK (1) SK283212B6 (de)
TW (1) TW518222B (de)
UA (1) UA70315C2 (de)
WO (1) WO1999040904A2 (de)
ZA (1) ZA991077B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2312990C (en) * 1997-12-08 2008-04-29 Bristol-Myers Squibb Company Novel salts of metformin and method
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
FR2796940B1 (fr) * 1999-07-26 2005-04-08 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US7151191B2 (en) * 2000-01-13 2006-12-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
JP4829411B2 (ja) * 2001-02-23 2011-12-07 キッセイ薬品工業株式会社 Ｃ型慢性肝炎治療剤
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
EP1424070A1 (de) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Zusammensetzung von einem PPAR-alpha Agonisten und Metformin zur Senkung des Serumtriglyceridspiegels
ATE411010T1 (de) 2002-12-13 2008-10-15 Jagotec Ag Topische nanopartikel-spironolacton-formulierung
FR2851734B1 (fr) * 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
US8062664B2 (en) * 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
ATE515261T1 (de) 2003-12-19 2011-07-15 Omega Bio Pharma Ip3 Ltd Zusammensetzungen zur behandlung von diabetes
EP1559419A1 (de) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmazeutische Darreichungsformen enthaltend Metformin und ein Fibrat, sowie deren Herstellungsprozesse
EP1714648A4 (de) * 2004-02-09 2010-05-26 Aska Pharm Co Ltd Kombinationsarzneimittel
EP1591114A1 (de) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Verwendung von Metformin und Orlistat zur Behandlung oder Vorbeugung von Obesität
US20060286182A1 (en) * 2005-06-21 2006-12-21 Abeille Pharmaceuticals, Inc. Synergistic cinnamon combinations and methods for enhancing insulin activity
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
US20090318496A1 (en) 2006-08-04 2009-12-24 Aska Pharmaceutical Co., Ltd. Preparation containing fibrate agent and process for producing the same
CN101342164B (zh) * 2007-08-21 2011-04-20 阜新市仙鹤制药有限责任公司 苯扎贝特控释制剂及其制备方法
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9339458B2 (en) * 2009-02-18 2016-05-17 Itf Research Pharma, S.L.U. Use of vaginal insulin sensitizing agents
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
MX2015000408A (es) * 2012-07-10 2015-07-14 Thetis Pharmaceuticals Llc Forma de triple sal de metformina.
US9382187B2 (en) * 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8765811B2 (en) * 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
WO2015183794A1 (en) 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
KR20170023061A (ko) 2014-06-18 2017-03-02 테티스 파마수티컬스 엘엘씨 활성제의 미네랄 아미노산 복합체
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
KR102437682B1 (ko) 2016-06-03 2022-08-29 테티스 파마수티컬스 엘엘씨 특화된 사전 해소 매개체의 염에 관한 조성물 및 방법
WO2018058109A1 (en) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
WO2023119100A1 (en) * 2021-12-22 2023-06-29 Mankind Pharma Ltd. Stable pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
FR2264525B1 (de) * 1974-03-22 1977-11-04 Expl Marques Brevets Et
DE3729209A1 (de) * 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
AU4050797A (en) * 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

Also Published As

Publication number Publication date
MY118164A (en) 2004-09-30
FR2774591A1 (fr) 1999-08-13
CA2320039A1 (en) 1999-08-19
AU746821B2 (en) 2002-05-02
NO20004056D0 (no) 2000-08-11
ID26254A (id) 2000-12-07
WO1999040904A2 (en) 1999-08-19
JP2002502869A (ja) 2002-01-29
RU2207850C2 (ru) 2003-07-10
SK11562000A3 (sk) 2000-12-11
AU2923399A (en) 1999-08-30
UA70315C2 (en) 2004-10-15
CZ20002828A3 (cs) 2000-11-15
EP1054665B1 (de) 2001-08-29
CN1290160A (zh) 2001-04-04
NO328314B1 (no) 2010-01-25
ES2162517T3 (es) 2001-12-16
HK1034913A1 (en) 2001-11-09
CZ290101B6 (cs) 2002-05-15
KR100567608B1 (ko) 2006-04-04
DK1054665T3 (da) 2001-12-27
PL342665A1 (en) 2001-07-02
SK283212B6 (sk) 2003-03-04
KR20010040925A (ko) 2001-05-15
ZA991077B (en) 1999-08-11
BRPI9907866B8 (pt) 2021-05-25
US6372790B1 (en) 2002-04-16
TW518222B (en) 2003-01-21
EP1054665A2 (de) 2000-11-29
ATE204754T1 (de) 2001-09-15
CN1151785C (zh) 2004-06-02
WO1999040904A3 (en) 1999-09-30
BR9907866A (pt) 2000-10-31
CA2320039C (en) 2008-07-22
NO20004056L (no) 2000-08-11
HUP0100801A2 (hu) 2001-08-28
BRPI9907866B1 (pt) 2017-08-15
HU224619B1 (hu) 2005-11-28
FR2774591B1 (fr) 2000-05-05
AR018286A1 (es) 2001-11-14
PL196874B1 (pl) 2008-02-29
DE69900249D1 (de) 2001-10-04
PT1054665E (pt) 2002-02-28
JP4767411B2 (ja) 2011-09-07
HUP0100801A3 (en) 2001-12-28

Similar Documents

Publication Publication Date Title
DE69900249T2 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
DE69720463D1 (de) Sulfonamid-derivate und ihre verwendung zur behandlung von zns-erkrankungen
DE69710095T2 (de) Pharmazeutische zubereitung zur behandlung von diabetes
DE69906671D1 (de) Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen
DE60204548D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
ATE318138T1 (de) Pharmazeutisches mittel zur behandlung von diabetes
DE60010456D1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
ATE238342T1 (de) Neue thrombin-inhibitoren, deren herstellung und verwendung
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
ATE260033T1 (de) Biozide zusammensetzung und deren verwendung
DE69804659T2 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
DE69812784D1 (de) Zusammensetzung zur Vorbeugung und Beseitigung von Pflanzenkrankheiten
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
ATE227278T1 (de) Substituierte benzylamine-derivate und ihre verwendung zur behandlung von depression
ATE254128T1 (de) Substituierte tricyclische verbindungen und deren verwendung zur behandlung von spla2-bedingten erkrankungen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE60001725D1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
ATE264309T1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
DE69925578D1 (de) Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten
DE59806627D1 (de) Arylsulfonamide und analoga und ihre verwendung zur behandlung von neurodegenerativen erkrankungen
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
DE69832722D1 (de) L-threonat-eisen, pharmazeutische zusammensetzung und verwendung zur verbesserung und behandlung von anämie bei menschen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition